BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Evopoint Biosciences Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Evopoint Biosciences Inc.'s drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06792435-2360@assetmemo.bio
DTSTAMP:20261121T010128Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:ASP546C: Phase 1/2 readout est. (NCT06792435)
DESCRIPTION:ASP546C\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: XNW27
 011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.\
 nEstimated primary completion: 30 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/asp546c#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06792435
URL:https://assetmemo.bio/drug/asp546c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07488676-2360@assetmemo.bio
DTSTAMP:20261121T010128Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:ASP546C: Phase 1/2 readout est. (NCT07488676)
DESCRIPTION:ASP546C\, phase 1/2.\nStudy: A Study of ASP546C in Adults With 
 Gastroesophageal Cancer\, Pancreatic Cancer or Other Solid Tumors\nEstimat
 ed primary completion: 31 July 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/asp546c#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07488676
URL:https://assetmemo.bio/drug/asp546c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
